COAG Hemab Therapeutics Holdings, Inc.

CIK 0002114044 3 ready 8-Ks latest May 21, 2026, 7:05 AM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 3

Latest filing May 21, 2026, 7:05 AM ET

Top materiality 0.85

Event mix earnings ×1 · leadership ×1 · other_material ×1

Sentiment 2 pos · 0 neg · 1 neu

Executive change recent →

Recent 8-K filings for COAG

Highest-materiality recent filing

Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

May 4, 2026, 7:59 PM ET other material materiality 0.85 positive item 5.03 item 8.01 item 9.01 ◈ Governance Changes ×2

IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.
Gross proceeds of $346.7 million before underwriting discounts and estimated offering expenses.

Read filing →

May 21, 2026, 7:05 AM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig

Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.
May 4, 2026, 7:59 PM ET other material materiality 0.85 positive item 5.03 item 8.01 item 9.01 ◈ Governance Changes ×2

Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.

Executive changes

Departed

Laura Tadvalkar

Director

COAG · Hemab Therapeutics Holdings, Inc.

Effective: 2026-05-08
Filed: May 11, 2026, 4:01 PM ET

On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event earnings

2 positive 0 negative 1 neutral

source · COAG on sec.gov